
Cancer therapy is associated with inherent adverse effects and the need for complete, consistent and accurate reporting of toxicity is paramount in zzso cooperative zzso clinical zzso zzso toxicity information is essential to weigh the costs and benefits associated with new treatment zzso A major issue faced by investigators and clinical trial coordinators today is the lack of clear directions regarding what method should be used in toxicity assessment in cooperative zzso clinical zzso Research personnel are faced with two options: zzso to be proactive and use a zzso method of toxicity assessment or zzso to simply follow the data trail and report selected toxicity based only on routine documentation in the zzso The differences between these two approaches may be immense depending on one's zzso The purpose of this article is to review how the current methods of toxicity assessment evolved and discuss issues and concerns in toxicity assessment in a challenging zzso environment where clinical trials continue to increase in complexity and workload through the use of novel and zzso zzso The potential implications for toxicity data management practices, data quality, patient care management and resource zzso are zzso 

